Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Kaleido Biosciences, Inc. (KLDO) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/08/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2022 8-K Quarterly results
01/28/2022 8-K Other Events  Interactive Data
11/01/2021 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2021 Financial Results --Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--"
10/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kaleido R&D Day Presentation, furnished herewith",
"Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile"
09/03/2021 8-K Other Events  Interactive Data
08/11/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/02/2021 8-K Appointed COO
06/17/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
Docs: "Third Amendment to Loan and Security Agreement, by and among Kaleido Biosciences, Inc. and each of its Qualified Subsidiaries (including Cadena Bio, Inc.), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement and Hercules Capital, Inc. †",
"Kaleido Biosciences Reports First Quarter 2021 Financial Results --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development--"
03/24/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
01/25/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement, by and between Kaleido Biosciences, Inc. and Katharine Knobil"
01/19/2021 8-K Quarterly results
01/14/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 2021 -"
10/13/2020 8-K Quarterly results
10/01/2020 8-K Quarterly results
08/04/2020 8-K Quarterly results
07/22/2020 8-K Quarterly results
06/18/2020 8-K Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Financial Statements and Exh...
Docs: "Second Amendment to Loan and Security Agreement, by and among Kaleido Biosciences, Inc. and each of its Qualified Subsidiaries (including Cadena Bio, Inc.), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement and Hercules Capital, Inc. †"
06/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Kaleido Biosciences Announces CEO Leadership Transition - Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter"
06/04/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 Par Value KLDO NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined...",
"Underwriting Agreement, by and between Kaleido Biosciences, Inc. and Morgan Stanley & Co. LLC",
"Opinion of Goodwin Procter LLP",
"Kaleido Biosciences Announces Proposed Public Offering of Common Stock",
"Kaleido Biosciences Announces Pricing of Public Offering of Common Stock"
05/14/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results - Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -",
"Corporate presentation of the Company, furnished herewith",
"Kaleido Biosciences Initiates Controlled Clinical Study of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19 - Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -"
05/08/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "By-laws Amendment",
"By-laws Amendment"
04/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 Par Value KLDO NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined...",
"Kaleido Biosciences Appoints Anne Prener, M.D., Ph.D., to its Board of Directors"
03/02/2020 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update"
01/07/2020 8-K Quarterly results
01/03/2020 8-K Quarterly results
12/12/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis",
"Corporate presentation of the Company"
11/06/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 Par Value KLDO NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined...",
"Kaleido Biosciences Appoints William Duke as Chief Financial Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy